2019-nCoV
Conditions
Brief summary
In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.
Detailed description
In December 2019, viral pneumonia caused by a novel beta-coronavirus (2019-nCoV) outbroke in Wuhan, China. Part of patients rapidly progress severe acute respiratory failure with substantial mortality, making it imperative to develop an efficient treatment for severe 2019-nCoV pneumonia besides the supportive care. Intravenous immunoglobulin (IVIG) has been shown to improve the treatment effect and prognosis of severe infection over the past decades with its capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect. We hypothesized that IVIG therapy would improve the prognosis of severe and critically ill patients with 2019-nCoV. This single-center, randomized, open-label, controlled trial will evaluate the efficacy and safety of IVIG therapy in patients with severe or critically ill 2019-nCoV respiratory disease.
Interventions
DRUGIntravenous Immunoglobulin
IVIG 0.5g/kg/d for 5 days
OTHERStandard care
Standard care
Sponsors
Tongji Hospital
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult aged \>=18years old; * Laboratory (RT-PCR) confirmed 2019-nCoV infection in throat swab and/or sputum and/or lower respiratory tract samples; * The interval between the onset of symptoms and randomized is within 7 days. The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used; * Meet any of the following criteria for severe or critical ill conditions: 1. Respiratory rate \>=30/min; or 2. Rest SPO2\<=90%; or 3. PaO2/FiO2\<=300mmHg; or 4. Respiratory failure and needs mechanical ventilation; or 5. Shock occurs; or 6. Multiple organ failure and needs ICU monitoring; * Sign the Informed Consent Form on a voluntary basis.
Exclusion criteria
* Exist of other evidences that can explain pneumonia including but not limited to: influenza A virus, influenza B virus, bacterial pneumonia, fungal pneumonia, noninfectious causes, etc.; * Allergy to Intravenous Immunoglobulin or its preparation components; * Patients with selective IgA deficiency * Women who are pregnant or breast-feeding; * Researchers consider unsuitable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement based on the 7-point scale | 28 days after randomization | A decline of 2 points on the 7-point scale from admission means better outcome. The 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death). |
| Lower Murray lung injury score | 7 days after randomization | Murray lung injury score decrease more than one point means better outcome. The Murray scoring system range from 0 to 4 according to the severity of the condition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of hospitalization | Measured from Day 0 through Day 28 | Days that a participant spent at the hospital. Multiple hospitalizations are summed up. |
| Proportion of patients with negative RT-PCR results | 7 and 14 days after randomization | Proportion of patients with negative RT-PCR results of virus in upper and/or lower respiratory tract samples. |
| Proportion of patients in each category of the 7-point scale | 7,14 and 28 days after randomization | Proportion of patients in each category of the 7-point scale, the 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death). |
| 28-day mortality | Measured from Day 0 through Day 28 | Number of deaths during study follow-up |
| Frequency of Adverse Drug Events | Measured from Day 0 through Day 28 | Frequency of Adverse Drug Events |
| Frequency of Serious Adverse Drug Events | Measured from Day 0 through Day 28 | Frequency of Serious Adverse Drug Events |
| Proportion of patients with normalized inflammation factors | 7 and 14 days after randomization | Proportion of patients with different inflammation factors in normalization range. |
| Duration of mechanical ventilation | Measured from Day 0 through Day 28 | Duration of mechanical ventilation use in days. Multiple mechanical ventilation durations are summed up. |
Contacts
Primary ContactTaisheng Li
Backup ContactWei Cao
Outcome results
None listed